Amwill Health Care Limited is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY25 | FY26 |
|---|---|---|
| Revenue | 41 | 45 |
| EBITDA (ex other income) | — | — |
| margin % | — | — |
| Owners' profit | — | — |
| EPS, as reported (₹) | 0.00 | 5.71 |
| ROE % · ROCE % | — · 17.1 | — · 19.0 |
| Debt / equity (x) | — | — |
| Cash from operations | 6 | 8 |
| Capex | (1) | (1) |
| ₹ crore | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|
| Revenue | 17 | 21 | 24 |
| Profit before tax | 3 | 5 | 10 |
| Net profit | — | — | — |
| EPS (₹) | 0.00 | 1.94 | 3.77 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 14 Aug 2026 · 9th AGM concluded; final dividend declared, both MDs re-appointed | board shareholder meetings | low | — | — |
| 8 Aug 2026 · Board approves investment limits of about 33 crore across multiple asset classes | business updates | medium | — | — |
| 8 Aug 2026 · Board re-appoints both Managing Directors for 5 more years | management changes | high | — | — |
| 23 Jul 2026 · Amwill Health Care opens Rs 2 crore fixed deposit with Vysya Bank | general | low | — | — |
| 23 Jul 2026 · Newspaper publication of 9th AGM notice and e-voting information | compliance | minimal | — | — |
| 22 Jul 2026 · 9th AGM on Aug 14, 2026; Final dividend of Rs 0.50/share; MD re-appointments | board shareholder meetings | low | — | — |
| 21 Jul 2026 · Newspaper notice for 9th AGM via video conferencing on August 14, 2026 | compliance | minimal | — | — |
| 17 Jul 2026 · Board fixes Aug 8 record date for 9th AGM, re-appoints both MDs | corporate actions | high | — | — |
| 17 Jul 2026 · Board approves MD reappointments, fixes 09th AGM on August 14, 2026 | corporate actions | high | — | — |
| 11 Jul 2026 · RTA compliance certificate for Q1 FY26-27 filed with BSE | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| 12.1 |
| 15.0 |
| AUROBINDO PHARMA LTD | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 7.5 | 28.9 | 16 of 169 | 91% |
| ROCE | 19.0 | 10.8 | 40 of 183 | 79% |
| Market cap | 86 | 839 | 139 of 182 | 24% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
